Friday, 20 Sep 2019

You are here

Proinflammatory Diets May Increase CRP and RA Onset

Despite the lack of good evidence, there has been great speculation about the role of diet in causing or alleviating inflammation. Now there's new research suggesting that proinflammatory diets can increase serum C-reactive protein (CRP) levels and also the risk of RA onset.

This study used a dietary survey called Dietary Inflammatory Index (DII) as a measure of dietary substances capable of augmenting inflammatory biomarkers. Diets with a high DII scores are associated with increased levels of CRP and interleukin-6. 

Patients in two large prospective registries, the European Prospective Investigation of Cancer (EPIC) and the Norfolk Arthritis Register (NOAR) were studied after linking databases.

The DII was calculated on healthy subjected being enrolled into EPIC between 1993 and 1998. Among the 25,522 EPIC patients they identified 159 who were subsequently diagnosed as RA from the NOAR registry. 

Comparison of highest and lowest quartiles of DII from EPIC enrollment revealed that high DII scores (proinflammatory diets) were associated with a higher risk of subsequent RA onset (DII: OR 1.90 [1.21-3.02]; p < 0.01).  However, when these analyses were adjusted for age, sex and BMI, the same level  significance was not achieved (OR 1.35 [0.85-2.19]; p = 0.2).

Diet may be one of the few modifiable factors that may influence inflammation and the risk of future RA onset. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Two vs. Four Weeks of Antibiotic Therapy in Septic Arthritis

A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.

This Swiss study was a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults. 

Bimekizumab Add-on Therapy in Rheumatoid Arthritis

Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis patients not adequately controlled by certolizumab pegol resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA.

74 Percent of Rheumatoid Arthritis Patients Dissatisfied with Treatment

CreakyJoints has completed a 258 patient survey showing that nearly three-fourths of people with rheumatoid arthritis (RA) have expressed dissatisfaction with their treatments, including conventional (csDMARDs) and biologic Disease Modifying Antirheumatic Drugs (bDMARDs).

RA Women are Less Likely to Breastfeed

A large pregnancy registry has published their results showing rheumatoid arthritis (RA) patients who become pregnant are less likely to breastfeed compared to non-RA women from the general population, with many women stopping breastfeeding so that they could start medication, even though many of these meds are safe to use during lactation.

Respiratory Risks Not Increased in RA Patients with COPD

An insurance claims based study of RA patients with COPD shows that biologics do not have an increased rate of respiratory events compared to those on conventional DMARDs. A real world cohort of RA patients with COPD was drawn from US-based MarketScan databases. Patients on biologic DMARDs and/or targeted synthetic DMARDs (tsDMARDs) were propensity matched to those on conventional synthetic DMARDs (csDMARDs).